alexion pharmaceuticals , inc . notes to consolidated financial statements 2014 ( continued ) for the years ended december 31 , 2007 and 2006 , five month period ended december 31 , 2005 , and year ended july 31 , 2005 ( amounts in thousands , except share and per share amounts ) in 2006 , we completed a final phase iii trial of pexelizumab . after reviewing results from that trial , we along with p&g , determined not to pursue further development of pexelizumab . effective march 30 , 2007 , we and p&g mutually agreed to terminate the collaboration agreement . as the relevant agreement has been terminated in march 2007 , the remaining portion of the $ 10000 non-refundable up-front license fee , or $ 5343 , was recognized as revenue in the year ended december 31 , 2007 and is included in contract research revenues . license and research and development agreements we have entered into a number of license , research and development and manufacturing development agreements since our inception . these agreements have been made with various research institutions , universities , contractors , collaborators , and government agencies in order to advance and obtain technologies and services related to our business . license agreements generally provide for an initial fee followed by annual minimum royalty payments . additionally , certain agreements call for future payments upon the attainment of agreed upon milestones , such as , but not limited to , investigational new drug , or ind , application or approval of biologics license application . these agreements require minimum royalty payments based on sales of products developed from the applicable technologies , if any . clinical and manufacturing development agreements generally provide for us to fund manufacturing development and on-going clinical trials . clinical trial and development agreements include contract services and outside contractor services including contracted clinical site services related to patient enrolment for our clinical trials . manufacturing development agreements include clinical manufacturing and manufacturing development and scale-up . we have executed a large-scale product supply agreement with lonza sales ag for the long-term commercial manufacture of soliris ( see note 9 ) . in order to maintain our rights under these agreements , we may be required to provide a minimum level of funding or support . we may elect to terminate these arrangements . accordingly , we recognize the expense and related obligation related to these arrangements over the period of performance . the minimum fixed payments ( assuming non-termination of the above agreements ) as of december 31 , 2007 , for each of the next five years are as follows : years ending december 31 , license agreements clinical and manufacturing development agreements .

Table:
years ending december 31, | license agreements | clinical and manufacturing development agreements
2008 | $ 707 | $ 2860
2009 | 552 | 3750
2010 | 322 | 7500
2011 | 300 | 7500
2012 | 300 | 7500
.

Question: what is the percent change in minimum fixed payments of clinical and manufacturing development agreements between 2008 and 2009?
Answer: 31.1%
Calculation: subtract(3750, 2860), divide(#0, 2860)